Last updated: April 25, 2026
Who supplies elagolix sodium (API) for combination products with estradiol and norethindrone acetate?
Elagolix sodium is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist used in multiple women’s health indications, including endometriosis. The key supplier set for elagolix sodium API is captured in the controlled supply chains and public filings for elagolix-containing products and related manufacturing authorizations.
What supplier landscape exists for elagolix sodium API?
The elagolix sodium API supply chain is tied to brand holders and their contract manufacturing and analytical testing networks, plus downstream specialty API suppliers that publish Chemical Abstracts and process grades. In practice, sourcing for elagolix sodium is constrained by:
- DMF and CEP-linked filings for the API and impurities
- Site qualification by the drug product holder
- Regulatory dossier dependencies for polymorph, particle size distribution, and impurity limits
Publicly available documentation most consistently identifies the API holder/manufacturer network through regulatory registrations and dossier linkages rather than open commercial procurement lists.
Which public records identify elagolix sodium API manufacturers and sites?
Public regulatory and dossier-linked sources generally show elagolix API manufacturing at specific sites named in marketing authorizations and registration summaries. The most reliable “supplier” identifiers in this context are:
- API manufacturer sites referenced in regulatory filings (DMF-linked manufacturers)
- Filing holders (companies that own or control the API dossier)
- Drug product manufacturers for combination products that list their upstream API sources
At a minimum, elagolix sodium API is sourced from companies that support GMP manufacture and dossier maintenance for elagolix-containing formulations.
What combination context matters for estradiol and norethindrone acetate products?
In fixed-dose combinations involving elagolix plus hormonal add-backs, the drug product manufacturer typically qualifies a specific elagolix API dossier (with defined impurity profiles and specifications) and combines it with estradiol and norethindrone acetate sourced through their own DMF/CEP-linked supply routes. For sourcing purposes, the practical question is not only “who sells elagolix sodium,” but which upstream API site is already approved under the product’s regulatory package.
Which procurement-ready supplier categories exist for elagolix sodium?
Because open commercial supplier lists vary in accuracy for niche APIs, practical supplier mapping is best done by triangulating:
- Regulatory dossier linked API suppliers (DMF/CEP)
- GMP API manufacturing site registrations (countries with drug authority public databases)
- Commercial API distributors that are authorized to resell the API from the registered manufacturers
The combination of these sources produces the actionable supplier set used by procurement teams.
Table: elagolix sodium supplier identification approach (evidence grade)
| Evidence type |
What it identifies |
Reliability for procurement |
Typical use |
| Regulatory marketing authorization references |
API manufacturing site(s) named in the approval package |
High |
Confirm “approved API” network |
| DMF/CEP-linked filings in authorities |
Filing holder and API manufacturing responsibilities |
High |
Trace impurity specs, polymorph control |
| GMP site registrations and inspections |
Site address and legal entity associated with manufacture |
Medium to high |
Validate manufacturing capability |
| Commercial reseller catalogs |
“Supplier” entity selling elagolix sodium |
Medium |
Lead generation, not final qualification |
Key takeaways for supplier sourcing decisions
- For elagolix sodium, the supplier set that matters operationally is the one tied to the approved regulatory dossier for the specific elagolix-containing product.
- Estradiol and norethindrone acetate procurement is usually less constrained than elagolix, but the drug product manufacturer controls API changeovers through dossier control.
- The most defensible route to an “approved supplier list” is regulatory-dossier triangulation (marketing authorization references plus DMF/CEP linked manufacturers), not reseller catalog claims.
Key Takeaways
- elagolix sodium API sourcing is dossier- and site-qualified; procurement teams should prioritize regulatory-linked API manufacturers and filing holders tied to the specific elagolix product package.
- Supplier identification should be built from marketing authorization and DMF/CEP references, then validated through GMP and change-control eligibility for the drug product manufacturer.
- In combination products with estradiol and norethindrone acetate, the drug product holder’s qualified API network is the binding constraint for elagolix supply continuity.
FAQs
1) Is elagolix sodium sourced from the same manufacturers across all elagolix products?
Not always. The approved API dossier and qualified manufacturing sites can differ by product and region. Procurement should follow the specific approved regulatory package.
2) What is the best evidence to identify “real” elagolix sodium suppliers?
Regulatory marketing authorization and DMF/CEP-linked filings that name API manufacturing sites and/or filing holders.
3) Can a reseller provide compliant elagolix sodium without being the API manufacturer?
Often yes, but compliance depends on whether the reseller supplies the same qualified dossier/API source used in the approved product package.
4) What elements of elagolix sodium specifications typically drive supplier qualification?
Impurity profile, polymorph/crystal form, particle size distribution, and analytical method validation tied to the regulatory dossier.
5) How do estradiol and norethindrone acetate sourcing affect elagolix API selection in combination drugs?
They usually do not change the elagolix API qualification requirements, but the overall product qualification process is controlled by the drug product manufacturer’s change-control system.
References
[1] European Medicines Agency. EPAR or product information for elagolix-containing products where applicable (API and manufacturing references in assessment documents). EMA.
[2] U.S. Food and Drug Administration. Drug approval packages for elagolix-containing products (review documents and manufacturing information where applicable). FDA.
[3] World Health Organization. Guidelines on the quality of synthetic drugs and general principles for drug substance control (relevance to supplier qualification). WHO.
